Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.
Heymach JV, et al. Among authors: van den abbeele ad.
Clin Cancer Res. 2004 Sep 1;10(17):5732-40. doi: 10.1158/1078-0432.CCR-04-0157.
Clin Cancer Res. 2004.
PMID: 15355900
Clinical Trial.